FDA approves Progenics' drug for rare tumors

Jul 31, 2018

The U.S. Food and Drug Administration (FDA) have approved the New Drug Application for Progenics Pharmaceuticals' azedra, a treatment for two types of rare adrenal gland tumors. This approval makes it the first drug approved in the United States for this purpose.

According to the FDA, the med is now able to treat patients older than 2 who have either pheochromocytoma or paraganglioma tumors and require anti-cancer therapy.

The regulator said the drug would be used to treat patients whose tumor has spread beyond the original site and cannot be surgically removed.

Read the full news release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments